CRChryslaine Rodríguez-Tanty

Chryslaine Rodríguez-Tanty

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chryslaine Rodríguez-Tanty has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CNEURO-201, an Anti-amyloidogenic Agent and σ1-Receptor Agonist, Improves Cognition in the 3xTg Mouse Model of Alzheimer’s Disease by Multiple Actions in the Pathology

    by Humberto Martínez-Orozco, Alberto Bencomo-Martínez, Juan Pablo Maya-Arteaga, Pedro Francisco Rubio-De Anda, Fausto Sanabria-Romero, Zyanya Gloria Mena Casas, Isaac Rodríguez-Vargas, Ana Gabriela Hernández-Puga, Marquiza Sablón-Carrazana, Roberto Menéndez-Soto del Valle, et al.

    The complexity of Alzheimer’s disease (AD) pathophysiology represents a significant challenge in the development of effective therapeutic agents for its treatment. CNEURO-201 (CN, also Amylovis-201) is a novel pharmaceutical agent with dual activity as an anti-amyloid-β (Aβ) agent and σ1 receptor agonist. CN exhibits great efficacy at very low doses, delaying cognitive impairment and alleviating Aβ load in animal models of AD. However, CN functions on other remains related to this pathology remain to be investigated. The present study sought to evaluate the effects of CN treatment at a dosage of 0.1 mg kg−1 (p.o) over an eight-week period in the 3xTg-AD mouse model. In silico studies, as well as biochemical and immunofluorescence assays, were conducted on brain tissue to investigate the CN effects on acetylcholine metabolism, redox system, and glial cell activation-related biomarkers in brain regions that are relevant for memory. The results demonstrated that CN effectively rescues cognitive impairment of 3xTg-AD mice by influencing glial activity to reduce existing Aβ plaques but also modulating acetylcholine metabolism and the enzymatic response of proteins involved in the redox system. Our outcomes reinforced the potential of CN in treating AD by acting on multiple pathways altered in this disease.


  • Open Access

    CNEURO-201, an Anti-Amyloidogenic Agent and σ1-Receptor Agonist Improves Cognition in the 3xTg Mouse Model of Alzheimer’s Disease by Multiple Actions in the Pathology

    by Humberto Martínez-Orozco, Alberto Bencomo-Martínez, Juan Pablo Maya-Arteaga, Pedro Francisco Rubio-De Anda, Fausto Sanabria Romero, Zyanya Gloria Mena Casas, Isaac Vargas-Rodríguez, Ana Gabriela Hernández-Puga, Marquiza Sablón-Carrazana, Roberto Menéndez Soto del Valle, et al.

    The complexity of Alzheimer’s disease (AD) pathophysiology represents a significant challenge in the development of effective therapeutic agents for its treatment. CNEURO-201 (CN, also Amylovis-201) is a novel pharmaceutical agent with dual activity as an anti-amyloid-β (Aβ) agent and σ1 receptor agonist. CN exhibits a great efficacy at very low doses, delaying cognitive impairment and alleviating Aβ load in animal models of AD. However, CN functions on other pathways related to this pathology remains to be investigated. The present study sought to evaluate the effects of CN treatment at a dosage of 0.1 mg kg-1 (p.o) over an eight-week period in the 3xTg-AD mouse model. In silico studies, as well as biochemical and immunofluorescence assays, were conducted on brain tissue to investigate the CN effects on acetylcholine metabolism, redox system and glial cell activation related biomarkers in brain regions that are relevant for memory. The results demonstrated that CN effectively rescues cognitive impairment of 3xTg-AD mice by influencing glial activity to reduce existing Aβ plaques, but also modulating acetylcholine metabolism and the enzymatic response of proteins involved in redox system. Our outcomes reinforced the potential of CN to treat AD by acting on multiple pathways altered in this disease.


  • Open Access

    Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the σ1 chaperone protein

    by Laura García-Pupo, Lucie Crouzier, Alberto Bencomo-Martínez, Johann Meunier, Axelle Morilleau, Benjamin Delprat, Marquiza Sablón Carrazana, Roberto Menéndez Soto del Valle, Tangui Maurice, Chryslaine Rodríguez-Tanty


  • Open Access

    Magnetic Nanoparticles Conjugated to Amylovis® as Contrast Agents, Synthesis and In Silico Evaluation

    by Claudia González, Alicia Díaz, Marquiza Sablón, Chryslaine Rodríguez

    Iron oxide nanoparticles (IONPs) have high relativity for Magnetic Resonance Imaging (MRI) and have shown a long half-life which can covalently bind with drugs and antibodies that can be used for increased contrast while imaging with MRI. IONPs are approved by the U.S Food and Drug Administration to be used as a contrast agent for MRI in vivo. The Cuban Neuroscience Center has developed a new family of naphthalene derivative compounds called Amylovis® to be used to diagnose and treatment of Alzheimer’s disease (AD). The goal of this work is to synthesize IONPs with different coatings to be conjugated to Amylovis® as contrast agents for MRI. Coprecipitation method was employed to obtain the magnetic nuclei, and two synthesis methodologies were performed to coat the IONPs (post-synthesis or in situ). The different coatings used were the following: (3-aminopropyl)triethoxysilane (APTES), dicarboxylic polyethyleneglycol, galic acid, polyacrylic acid and citrate. Carbodiimide method was used as synthetic protocol to conjugate the Amylovis® moiety to different coatings. The nanoparticles were characterized by DRX, FT-IR, Electrophoretic Light Scattering (ELS) and Dynamic Light Scattering (DLS). Moreover, the stability of nanoparticles in water was evaluated using a sedimentation curve. In order to determine the potential interaction of nanosystems with the beta amyloid peptides, a molecular docking was carried out. The theoretical study showed that coatings do not affect the interaction of Amylovis® with the receptor, and the new polar groups incorporated increased the affinity to receptor.

  • A new naphthalene derivative with anti-amyloidogenic activity as potential therapeutic agent for Alzheimer's disease

    by Suchitil Rivera-Marrero, Alberto Bencomo-Martínez, Erika Orta Salazar, Marquiza Sablón-Carrazana, Laura García-Pupo, Florencia Zoppolo, Florencia Arredondo, Rosina Dapueto, María Daniela Santi, Ingrid Kreimerman, et al.


  • Open Access

    Drug Development in Conformational Diseases: A Novel Family of Chemical Chaperones that Bind and Stabilise Several Polymorphic Amyloid Structures

    by Marquiza Sablón-Carrazana, Isaac Fernández, Alberto Bencomo, Reyna Lara-Martínez, Suchitil Rivera-Marrero, Guadalupe Domínguez, Rafaela Pérez-Perera, Luis Felipe Jiménez-García, Nelly F. Altamirano-Bustamante, Massiel Diaz-Delgado, et al.

    The increasing prevalence of conformational diseases, including Alzheimer's disease, type 2 Diabetes Mellitus and Cancer, poses a global challenge at many different levels. It has devastating effects on the sufferers as well as a tremendous economic impact on families and the health system. In this work, we apply a cross-functional approach that combines ideas, concepts and technologies from several disciplines in order to study, in silico and in vitro, the role of a novel chemical chaperones family (NCHCHF) in processes of protein aggregation in conformational diseases. Given that Serum Albumin (SA) is the most abundant protein in the blood of mammals, and Bovine Serum Albumin (BSA) is an off-the-shelf protein available in most labs around the world, we compared the ligandability of BSA:NCHCHF with the interaction sites in the Human Islet Amyloid Polypeptide (hIAPP):NCHCHF, and in the amyloid pharmacophore fragments (Aβ17–42 and Aβ16–21):NCHCHF. We posit that the merging of this interaction sites is a meta-structure of pharmacophore which allows the development of chaperones that can prevent protein aggregation at various states from: stabilizing the native state to destabilizing oligomeric state and protofilament. Furthermore to stabilize fibrillar structures, thus decreasing the amount of toxic oligomers in solution, as is the case with the NCHCHF. The paper demonstrates how a set of NCHCHF can be used for studying and potentially treating the various physiopathological stages of a conformational disease. For instance, when dealing with an acute phase of cytotoxicity, what is needed is the recruitment of cytotoxic oligomers, thus chaperone F, which accelerates fiber formation, would be very useful; whereas in a chronic stage it is better to have chaperones A, B, C, and D, which stabilize the native and fibril structures halting self-catalysis and the creation of cytotoxic oligomers as a consequence of fiber formation. Furthermore, all the chaperones are able to protect and recondition the cerebellar granule cells (CGC) from the cytotoxicity produced by the hIAPP20–29 fragment or by a low potassium medium, regardless of their capacity for accelerating or inhibiting in vitro formation of fibers. In vivo animal experiments are required to study the impact of chemical chaperones in cognitive and metabolic syndromes.


  • Non‐Enzymatic In Vitro DNA Labeling and Label Immunoquantification

    by David Higginson Clarke, Dannelys Pérez‐Bello, Ana María Riverón‐Rojas, Esteban Gutiérrez Calzado, Guillermo Jiménez‐Alemán, Mirta Zayas Acosta, Rafaela Pérez Perera, Marquiza Sablón Carrazana, Nelson Díaz Miranda, Chryslaine Rodríguez‐Tanty

    In the present work, a label immunoquantification procedure was developed in order to determine the number of markers introduced into DNA. A non‐enzymatic, in vitro labeling method for introducing the p‐bromobenzoyl radical (label), through transamination and acylation reactions of the cytidine nucleotides in calf thymus DNA, was carried out. Three spacer arms with different lengths were used for separating the label from the nucleotide and three labeled DNA were obtained. Anti‐p‐bromobenzoyl chicken IgY polyclonal antibodies were obtained. The antibodies detected the label, into three‐labeled DNA, with different sensitivities, in relation to spacer arm length used. About 3–11 labels per 4 × 106 bases into thermally denatured DNA were immunoquantified.